The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population.

Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. We sought to characterize the molecular landscape of high-risk breast cancer patients enrolled onto an adjuvant chemotherapy study to understand how disease subsets and tumor immune status impact survival. DNA and RNA were extracted from 861 breast cancer samples from patients enrolled onto the United States Oncology trial 01062. Samples were characterized using multiplex gene expression, copy number, and qPCR mutation assays. HR patients with a mutant tumor had a favorable disease-free survival (DFS; HR 0.66, =0.05), however, the prognostic effect was specific to luminal A patients (Luminal A: HR 0.67, =0.1; Luminal B: HR 1.01, =0.98). Molecular subtyping of triple-negative breast cancers (TNBCs) suggested that the mesenchymal subtype had the worst DFS, whereas the immunomodulatory subtype had the best DFS. Profiling of immunologic genes revealed that TNBC tumors (=280) displaying an activated T-cell signature had a longer DFS following adjuvant chemotherapy (HR 0.59, =0.04), while a distinct set of immune genes was associated with DFS in HR cancers. Utilizing a discovery approach, we identified genes associated with a high risk of recurrence in HR patients, which were validated in an independent data set. Molecular classification based on PAM50 and TNBC subtyping stratified clinical high-risk patients into distinct prognostic subsets. Patients with high expression of immune-related genes showed superior DFS in both HR and TNBC. These results may inform patient management and drug development in early breast cancer.